<DOC>
	<DOCNO>NCT01407471</DOCNO>
	<brief_summary>The purpose study determine whether spironolactone could significantly reduce cutaneous atrophy due corticosteroid .</brief_summary>
	<brief_title>Interest Topical Spironolactone 's Administration Prevent Corticoid-induced Epidermal Atrophy</brief_title>
	<detailed_description>skin cutaneous atrophy due corticosteroid limit long-term use highly potent topical glucocorticoid treatment choice many inflammatory skin disease . This atrophy result fragile skin , delay healing , purpura , irreversible stria , telangiectasia secondary infection . Up , treatment prevent efficiently skin atrophy . The mineralocorticoid receptor , belong superfamily nuclear receptor , express human epidermis actual function unknown . Experimental result animal obtain INSERM unit U772 Dr N FARMAN suggest spironolactone mineralocorticoid receptor antagonist 1- might limit epidermal atrophy 2- might promote heal . Study description We propose test clinically hypotheses first time human , CIC BICHAT 's hospital healthy volunteer : 1- apply skin highly potent cutaneous corticosteroid association spironolactone , 2- apply spironolactone wound 3-mm punch biopsy .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>Healthy volunteer sex , age 20 50 year Woman effective contraception pregnancy test negative inclusion . Subject consider healthy detail review ( interview , clinical examination ) Subject belong social security scheme ( beneficiary right ) Subject sign free inform consent Integrity skin forearm Subject available next 7 week able go CIC day Monday Friday Subject accept four skin biopsy D29 wash forearm 2 hour application Chronic Alcoholism Drugaddiction ( comprehensive interview sample case doubt ) Woman pregnant breastfeeding Subject involve another trial exclusion period another protocol Subject already receive 3700 Euros compensation damage suffer constraint past 12 month involvement biomedical research Subject already participate protocol Phototypes 5 6 Clinical skin atrophy History severe chronic skin disease Problems heal Treatment oral corticosteroid , mineralocorticoid spironolactone ( Aldactone , Flumach , Practon , Spiroctan , Spironone , Aldactazine , ALDALIX , Practazin , Spiroctazine ... )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>aldosterone</keyword>
	<keyword>clobetasol</keyword>
	<keyword>atrophy</keyword>
	<keyword>skin</keyword>
	<keyword>epidermis</keyword>
	<keyword>wound healing</keyword>
	<keyword>mineral corticoid receptor</keyword>
	<keyword>spironolactone</keyword>
</DOC>